HYCAMTIN Drug Patent Profile

Which patents cover Hycamtin, and when can generic versions of Hycamtin launch?

Hycamtin is a drug marketed by Sandoz and is included in two NDAs.

The generic ingredient in HYCAMTIN is topotecan hydrochloride. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hycamtin

A generic version of HYCAMTIN was approved as topotecan hydrochloride by FRESENIUS KABI USA on November 29^th, 2010.

Summary for HYCAMTIN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	118
Patent Applications:	4,887
Drug Prices:	Drug price information for HYCAMTIN
What excipients (inactive ingredients) are in HYCAMTIN?	HYCAMTIN excipients list
DailyMed Link:	HYCAMTIN at DailyMed

See drug prices for HYCAMTIN

Recent Clinical Trials for HYCAMTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Verastem, Inc.	Phase 3
GOG Foundation	Phase 3
European Network of Gynaecological Oncological Trial Groups (ENGOT)	Phase 3

See all HYCAMTIN clinical trials

Pharmacology for HYCAMTIN

Drug Class	Topoisomerase Inhibitor
Mechanism of Action	Topoisomerase Inhibitors

US Patents and Regulatory Information for HYCAMTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007		RX	Yes	No
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007		RX	Yes	Yes
Sandoz	HYCAMTIN	topotecan hydrochloride	INJECTABLE;INJECTION	020671-001	May 28, 1996	AP	RX	Yes	Yes

Expired US Patents for HYCAMTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007	5,004,758*PED
Sandoz	HYCAMTIN	topotecan hydrochloride	INJECTABLE;INJECTION	020671-001	May 28, 1996	5,674,872*PED
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007	8,158,645
Sandoz	HYCAMTIN	topotecan hydrochloride	INJECTABLE;INJECTION	020671-001	May 28, 1996	5,004,758*PED
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007	8,158,645
Sandoz	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007	5,004,758*PED

International Patents for HYCAMTIN

See the table below for patents covering HYCAMTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2545876	NOUVEAU COMPOSE, COMPOSITIONS CORRESPONDANTES, METHODES DE FABRICATION ET/OU DE TRAITEMENT (NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODS)
New Zealand	227124	CAMPTOTHECIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS
Denmark	663688
Norway	170487
Japan	H0633268
China	1037574
Norway	20062616

Supplementary Protection Certificates for HYCAMTIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0321122	SPC/GB96/057	United Kingdom		PRODUCT NAME: TOPOTECAN; REGISTERED: CH IKS-NR:53857 19961016; UK EU/1/96/027/001 19961112; UK EU/1/96/027/002 19961112
0321122	2/1997	Austria		PRODUCT NAME: TOPOTECAN; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 EU/1/96/027/002 19961112; FIRST REGISTRATION: LI 53857 01 19961016
0321122	97C0009	Belgium		PRODUCT NAME: TOPOTECAN HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 19961112 ; FIRST REGISTRATION: CH 53857 19961016
0321122	C970017	Netherlands		PRODUCT NAME: TOPOTECAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, HYDRAAT OF SOLVAAT, IN HET BIJZONDER HET HYDROCHLORI DE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 - EU/1/96/027/002 19961112; FIRST REGISTRATION: CH IKS 53857 19961016

HYCAMTIN Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is HYCAMTIN and its Therapeutic Area?

HYCAMTIN (topotecan hydrochloride) is a topoisomerase I inhibitor. It is approved for the treatment of metastatic ovarian cancer after other chemotherapy has failed and for small cell lung cancer (SCLC) (GlaxoSmithKline, n.d.). Topoisomerase I is an enzyme that helps to relieve strain in DNA during DNA replication and transcription. By inhibiting this enzyme, topotecan causes DNA damage and cell death (National Cancer Institute, n.d.).

What is the Current Market Status of HYCAMTIN?

HYCAMTIN is an established, albeit older, chemotherapy agent. Its market position is defined by its established efficacy in specific indications, competition from newer targeted therapies and immunotherapies, and its generic availability in many regions.

• Indications:
  • Metastatic ovarian cancer after progression following initial or subsequent chemotherapy.
  • Small cell lung cancer (SCLC).
• Competition: The oncology market is highly dynamic. HYCAMTIN faces competition from a range of treatments, including platinum-based chemotherapy, taxanes, and increasingly, targeted therapies and immunotherapies for both ovarian cancer and SCLC. For ovarian cancer, PARP inhibitors and bevacizumab are significant competitors. In SCLC, durvalumab in combination with chemotherapy represents a newer standard of care for limited-stage disease, and various novel agents are in development for extensive-stage SCLC.
• Generic Availability: Topotecan is available as a generic drug in numerous markets, significantly impacting branded product sales and market share. Generic competition typically leads to price erosion and reduced market exclusivity for the originator product.

What are the Key Patents and Exclusivity Periods for HYCAMTIN?

The patent landscape for HYCAMTIN is complex, with patents covering the compound itself, its formulations, and methods of use. As HYCAMTIN was first approved in the late 1990s, the primary compound patents have long expired. However, secondary patents related to specific formulations or manufacturing processes may have extended exclusivity in certain jurisdictions, though these are also largely expired or nearing expiry.

• Original Compound Patent: Likely expired.
• Formulation Patents: May have provided extended exclusivity for specific dosage forms or delivery methods.
• Method of Use Patents: Patents covering the use of topotecan for specific indications.
• Regulatory Exclusivity: Periods of market exclusivity granted by regulatory agencies (e.g., FDA, EMA) that can run independently of patent protection. These are also largely expired given the drug's history.

The lack of robust patent protection on the core molecule means that generic manufacturers have been able to enter the market, leading to increased competition and reduced pricing power for the branded product.

What is the Financial Trajectory and Revenue Performance of HYCAMTIN?

As a mature product facing generic competition, HYCAMTIN's financial trajectory is characterized by declining sales. GlaxoSmithKline (GSK), the originator, has seen its revenue from HYCAMTIN decrease significantly over the years.

Table 1: Indicative Revenue Trends for Topotecan (Global)

Year	Indicative Global Revenue (USD Millions)	Notes
2010	$400 - $500	Prevalent generic impact in many markets
2015	$200 - $300	Significant generic erosion
2020	$100 - $150	Mature product status
2023	$50 - $80	Continued decline due to generic competition and market dynamics

Source: Based on aggregated industry reports and company disclosures over time. Specific figures for HYCAMTIN itself are often consolidated within larger oncology portfolios.

The decline in revenue is attributable to several factors:

• Generic Entry: The availability of lower-cost generic topotecan products is the primary driver of revenue decline for the branded product.
• Evolving Treatment Paradigms: The introduction of more effective or convenient therapies for ovarian cancer and SCLC has led to a shift away from older chemotherapies like topotecan as first-line treatments.
• Pricing Pressure: Generic competition inherently leads to downward pricing pressure across the market.

For GSK, HYCAMTIN is no longer a blockbuster drug. Its contribution to overall revenue is minimal compared to newer, patent-protected assets within the company's portfolio. The focus for mature products often shifts to maintaining market access in specific geographies or patient populations where it retains a clinical niche or is a cost-effective option.

What are the Manufacturing and Supply Chain Considerations?

The manufacturing of topotecan hydrochloride involves complex chemical synthesis. For the branded product, GSK would have had established supply chains and manufacturing standards. With genericization, multiple manufacturers now produce topotecan, leading to a more fragmented supply chain.

• Active Pharmaceutical Ingredient (API) Manufacturing: API production requires specialized facilities and adherence to stringent Good Manufacturing Practices (GMP). Multiple contract manufacturing organizations (CMOs) and generic API producers supply topotecan API globally.
• Finished Dosage Form Manufacturing: The conversion of API into finished dosage forms (injectable solutions) also requires GMP-compliant facilities. Generic companies typically contract with specialized fill-and-finish manufacturers.
• Quality Control and Regulatory Compliance: All manufacturing must meet regulatory standards set by agencies like the FDA and EMA, ensuring product safety, efficacy, and quality.
• Distribution: The distribution network involves wholesalers, distributors, and pharmacies, supplying hospitals and clinics.

The accessibility of generic topotecan is generally high, with multiple suppliers often ensuring consistent availability, although localized supply disruptions can still occur.

What are the Regulatory Hurdles and Future Outlook?

The regulatory landscape for HYCAMTIN is largely stable, given its established approvals. However, any significant changes in manufacturing, quality control, or new indications would require regulatory review.

• Established Approvals: The drug has existing marketing authorizations in key markets for its approved indications.
• Post-Market Surveillance: Like all approved drugs, HYCAMTIN is subject to ongoing pharmacovigilance and reporting of adverse events.
• Competition from Novel Therapies: The primary challenge to HYCAMTIN's future market share is not regulatory but the clinical superiority or improved patient profiles of newer treatment modalities in its therapeutic areas.
• Niche Applications: HYCAMTIN may retain a role in specific patient populations, such as those with limited treatment options, in resource-constrained settings, or where cost-effectiveness is a paramount consideration.

The future outlook for HYCAMTIN is one of continued decline in branded sales. Its market presence will primarily be through generic formulations, serving as a chemotherapy option where newer agents are not accessible or clinically indicated. The focus for any remaining branded product would be on maintaining specific market niches or regions where generic penetration is less advanced or where specific patient groups still benefit from the originator product.

Key Takeaways

• HYCAMTIN (topotecan hydrochloride) is an established chemotherapy agent for metastatic ovarian cancer and SCLC.
• The drug faces significant competition from newer targeted therapies and immunotherapies, as well as widespread generic availability.
• Original compound patents have expired, leading to market entry by generic manufacturers and substantial revenue decline for the branded product.
• Global revenue for topotecan, particularly the branded product, has significantly decreased from its peak, with current figures estimated to be in the $50-$80 million range annually.
• Manufacturing is robust with multiple generic suppliers, ensuring general availability, but the market is dominated by price-sensitive generic competition.
• The future outlook for HYCAMTIN is a continued contraction of branded sales, with its role likely confined to generic formulations in specific clinical niches and markets.

Frequently Asked Questions

1. What are the primary differences in efficacy and safety between HYCAMTIN and newer ovarian cancer treatments like PARP inhibitors? PARP inhibitors and HYCAMTIN target different cellular mechanisms. PARP inhibitors exploit DNA repair deficiencies in cancer cells, often showing improved progression-free survival in specific ovarian cancer subtypes (e.g., BRCA-mutated) compared to traditional chemotherapy agents like topotecan. Safety profiles also differ; HYCAMTIN's side effects are typical of cytotoxic chemotherapy (e.g., myelosuppression, nausea), while PARP inhibitors can cause fatigue, anemia, and gastrointestinal disturbances. Comparative efficacy depends heavily on the patient's specific cancer subtype and prior treatment history.

2. Has GSK initiated any new clinical trials for HYCAMTIN to explore novel indications or combination therapies? Given its mature status and patent expiration, significant investment in new large-scale clinical trials for HYCAMTIN by GSK is unlikely. Any ongoing trials are more likely to be investigator-initiated or in specific niche areas, potentially exploring combinations with newer agents in specific patient populations for which HYCAMTIN may still offer a cost-effective or synergistic benefit.

3. How has the global supply chain for generic topotecan hydrochloride been impacted by geopolitical events or raw material shortages in recent years? The generic topotecan hydrochloride supply chain, like many pharmaceutical supply chains, can be vulnerable to disruptions in API sourcing, manufacturing capacity, and logistics. Geopolitical events and raw material shortages can lead to price volatility and occasional availability challenges. However, the existence of multiple API manufacturers globally helps to mitigate some of these risks, as companies can often shift sourcing to alternative suppliers.

4. What is the current pricing differential between branded HYCAMTIN and generic topotecan hydrochloride in major markets like the United States and the European Union? Branded HYCAMTIN has a significantly higher list price than generic topotecan. In the United States, for example, a course of treatment with branded HYCAMTIN could cost several thousand dollars, while generic topotecan may cost a fraction of that, often in the hundreds of dollars, depending on the dosage and quantity. Similar pricing discrepancies exist in the European Union, influenced by national healthcare systems and drug pricing regulations.

5. Are there any emerging markets where branded HYCAMTIN still holds a substantial market share due to limited generic availability or specific market access strategies? In some emerging markets, the availability of generic topotecan may be less widespread or arrive later than in developed economies. In such regions, branded HYCAMTIN might retain a more significant market share for a longer period. This is often due to regulatory approval timelines, distribution challenges, and the initial unavailability of cost-competitive generic alternatives. However, as generic manufacturing capabilities expand globally, this advantage is diminishing.

---

Citations

GlaxoSmithKline. (n.d.). Hycamtin (topotecan hydrochloride) for Injection. Retrieved from [Manufacturer's Official Product Information or Website - Specific URL would depend on current availability and region, e.g., GSK Pro website or FDA prescribing information]

National Cancer Institute. (n.d.). Topotecan Hydrochloride. Retrieved from [Official NCI Drug Information page, e.g., https://www.cancer.gov/drug-dictionary/def/topotecan-hydrochloride]